Zymeworks (NASDAQ:ZYME) is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. The company specializes in engineered antibody and protein therapeutics designed to address a range of unmet medical needs in oncology and other serious diseases. Through its proprietary platforms, Zymeworks aims to create novel bispecific and multispecific molecules that can simultaneously engage multiple targets and recruit immune effector functions to enhance potency and specificity.
At the core of Zymeworks’ innovation is its Azymetric™ bispecific antibody platform, which enables the design of asymmetrical bispecific antibodies with controlled assembly and high stability. Complementing this is the Torque™ antibody–drug conjugate (ADC) platform, which empowers precise conjugation of cytotoxic payloads to antibodies for targeted cancer therapy. The company also leverages its Engine™ protein engineering and Armory™ discovery platforms to optimize binding affinity and multispecific formats, as well as to streamline the identification of novel therapeutic candidates.
Zymeworks’ clinical pipeline features multiple product candidates, including ZW25, a biparatopic antibody targeting two distinct domains of the human epidermal growth factor receptor 2 (HER2) for treatment of solid tumors, and ZW49, an ADC derived from ZW25 equipped with a cytotoxic payload. Another notable candidate is zenocutuzumab (ZW25-ADC), designed to target neuregulin 1 (NRG1) fusion-driven cancers. These programs underscore the company’s strategic focus on hard-to-treat oncology indications and its commitment to advancing therapies through clinical development in collaboration with global partners.
Founded in 2003 and headquartered in Vancouver, British Columbia, Zymeworks operates research and development facilities in both Canada and the United States. Under the leadership of President and Chief Executive Officer Andrew Lo, Ph.D., the company maintains strategic alliances with pharmaceutical partners and academic institutions worldwide. Zymeworks continues to expand its geographic reach and scientific collaborations as it pursues regulatory submissions and potential commercialization of its innovative biotherapeutic candidates.
